Biotech Values

[iwfal]

RVNC Agree it will have overwhelming efficacy. At start. And I have no doubt that they can get approval in the indication using the data. But the ability to penetrate the market is dependent on better initial efficacy and/or better duration. And for both of those I’d suggest the signal likely will be harder to see now.

That said, they might well be able to work w FDA before unblinding to get some pre-agreed rules. Assuming the FDA is even returning calls right now. And if they aren’t returning calls, at least Revance should have a plan.